The surgery, performed on August 25 by Dr. Torsten P. Vahl and his team, addressed severe functional mitral regurgitation using a percutaneous, transseptal approach. Doctors reported an excellent hemodynamic result, effectively eliminating the patient's regurgitation. The Saturn system is engineered to navigate anatomical variability and mitigate the risk of left ventricular outflow tract obstruction, a common hurdle in traditional valve replacement procedures.

This U.S. milestone follows extensive testing in Europe, where the CASSINI-EU study has tracked subjects for over two years. Data from the European cohort shows no procedural mortality and consistent reduction of mitral regurgitation to mild levels in all implanted cases. InnovHeart CEO David J. Wilson noted that these results, combined with the successful U.S. debut, demonstrate the platform's stability and readiness for further clinical evaluation. The Saturn system remains strictly for investigational use as the company continues to collect performance data.